Cardiogen

Cardiogen is a synthetic tetrapeptide made of four amino acids: alanine, glutamic acid, aspartic acid, and arginine (Ala-Glu-Asp-Arg, or AEDR). It belongs to the Khavinson family of short peptide bioregulators developed at the S.M. Kirov Military Medical Academy ¹.

Its research focus is the heart. In an adrenaline stress model, injected Cardiogen moved elevated heart rate back toward control, reduced irregular rhythms (arrhythmia), and reversed stress-related changes in heart, adrenal, and spleen mass ². In cell culture, it increased expression of structural proteins that give heart-muscle cells their internal framework ³. The entire evidence base is preclinical; no human trial exists.

A naming note matters for anyone searching the literature. CardioGen-82 is a separate product, a strontium-82/rubidium-82 generator used for cardiac PET imaging. FDA alerts and recalls about that device do not describe this peptide ⁷.

Cardiogen is not a classic receptor-binding hormone. The working model is gene-expression regulation: short peptides in this family interact directly with DNA and influence transcription, protein synthesis, and chromatin state ¹. Cardiogen's specific tetrapeptide, AEDR, stimulates expression of cytoskeletal and nuclear matrix proteins ³.

Cytoskeletal proteins form the internal scaffolding of a cell, including the contractile architecture heart-muscle cells need to beat. Nuclear matrix proteins help organize the nucleus and the machinery that reads genes. The hypothesis is that stress or aging lowers these structural programs, and Cardiogen nudges them back toward baseline rather than over-activating them ¹.

A second layer is cardiovascular. In rats under adrenaline stress, Cardiogen blunted the rise in heart rate, reduced arrhythmia, and normalized stress-related shifts in heart, adrenal, and spleen mass ². Exposure of myocardial tissue cultures from young and old rats also changed tissue development, suggesting a direct effect on heart tissue rather than only whole-body signaling ⁵.

All documented Cardiogen effects come from animal studies, cell and tissue cultures, or the broader Khavinson peptide class. Strength of evidence is noted for each.

• Heart-rate normalization under stress: Injected Cardiogen returned adrenaline-elevated heart rate to control values and reduced arrhythmic events in rats ². Animal evidence, moderate strength.
• Organ-mass normalization: The same stress model showed reversal of stress-related shifts in relative heart, adrenal, and spleen mass ². Animal evidence.
• Structural protein expression: AEDR stimulated cytoskeletal and nuclear matrix protein expression in cell experiments ³. In-vitro evidence.
• Myocardial tissue growth: Cardiogen combined with amino acids modulated development of myocardial tissue explants from young and old rats ⁵. In-vitro evidence.
• Tumor modification: In senescent rats carrying M-1 sarcoma, Cardiogen had a modifying effect, but the direction and magnitude are not described in the available abstract ⁴. Animal evidence, low confidence.
• Class-level longevity and regulatory effects: Across the broader short-peptide family, treated animals showed reduced tumor incidence, normalized melatonin, and extended mean lifespan ¹. These are family-level findings, not Cardiogen-specific.

None of these outcomes has been confirmed in a human trial.

Published Cardiogen experiments used injectable routes, but the abstracts do not report unit doses. In rats, injection normalized heart rate and rhythm during adrenaline stress ². In senescent rats, chronic injection modified M-1 sarcoma growth ⁴. Myocardial tissue explants were exposed directly in culture for the tissue-growth work ⁵.

Because no human trial has established a dose, human-scale schedules come from community and practitioner protocols rather than trial data. The common pattern is 1-10 mg by intramuscular or subcutaneous injection once daily for 10 days, followed by 3-6 months off before a repeat course. Dosing is typically reported as a flat course rather than scaled to body weight, and no weight-adjusted human data exist.

Timing is empiric. Practitioner guidance usually defaults to morning administration for adherence, but no chronopharmacology data exist. The rat stress model shows the peptide counters adrenaline-induced heart-rate and rhythm changes ², but that does not translate into a rule around exercise or stimulant timing.

Cardiogen is distributed either as a ready-to-use solution or as a dry (lyophilized) powder that requires mixing before research use. For powder, the recommended diluent is bacteriostatic water for injection when the same vial will be used across days, or sterile water for single use.

Mix by letting the diluent run down the vial wall and then rolling the vial gently. Avoid shaking, which can stress the peptide. Once prepared, keep the solution refrigerated at 2-8°C and protected from light. Community guidance is to discard multi-dose vials with a preservative after 30 days, and preservative-free single-use vials within 24 hours. Do not freeze the prepared solution.

The calculator below handles the dilution and dose-volume math. No published forced-degradation data exist for Cardiogen, but short tetrapeptides without disulfide bonds are generally stable under these handling conditions. Discard any vial that turns cloudy, discolored, or contains particles.

Cardiogen has no human drug-interaction studies, so this profile is inferred from its rat stress model and gene-expression mechanism ¹.

Drug class notes

• Beta-agonists and sympathomimetics: Because Cardiogen dampened adrenaline-driven heart-rate and arrhythmia changes in rats, it may blunt the heart-rate response to epinephrine, pseudoephedrine, or ADHD stimulants ². No human data confirm this.
• Negative chronotropes: Beta-blockers, ivabradine, and digoxin lower heart rate by other mechanisms. The animal data suggest possible additive heart-rate reduction with Cardiogen ², so practitioner guidance is to monitor resting heart rate and rhythm closely.
• Anticoagulants and antiplatelets: No interaction has been reported, and the documented molecular target is structural-protein expression ³.
• Chemotherapy and targeted agents: Cardiogen changed sarcoma course in aged rats, but the direction is unclear ⁴. Community guidance separates a Cardiogen course from chemotherapy unless an oncology team agrees.

Supplement notes

High-dose stimulants such as caffeine above roughly 300 mg daily, synephrine, or yohimbine may oppose the peptide's stress-dampening profile. Adaptogens including ashwagandha and L-theanine, plus CoQ10, magnesium, and omega-3, are commonly co-administered without reported conflict, but no controlled interaction studies exist.

No trial defines Cardiogen scheduling, so every human-scale cycle is community or practitioner based. The standard pattern is a 10-day daily course, then at least 3-6 months off before the next course. Some practitioners allow up to 20 days on, and some use a paired block: 10 days on, 10-20 days off, 10 days on, then a longer rest.

The cycle logic follows the mechanism. A gene-expression regulator should plateau once expression patterns normalize, which fits episodic rather than continuous dosing ¹. The rat stress model also showed measurable heart-rate, rhythm, and organ-mass normalization after a discrete injectable course ². Classical receptor desensitization is not the main concern; course-based use reflects the slow, persistent nature of transcriptional changes.

Reported reasons to pause include return of stress-related tachycardia, diminished subjective benefit, injection-site reactions, and new abnormal laboratory findings. Because no chronic human safety data exist, practitioners generally do not extend beyond 20 consecutive days without a washout.

Cardiogen is often run alongside other Khavinson short-peptide bioregulators such as Epitalon, Thymalin, or Vesugen. The common community approach uses two or three bioregulators at their standard doses during the same 10-day course, repeated every 3-6 months ¹. No formal interaction studies exist for these combinations, but they share the same short-peptide design.

Combining Cardiogen with BPC-157 or TB-500 is also discussed. The mechanisms are described as complementary: gene-expression restoration versus repair and angiogenesis signaling. Since no conflict data exist, practitioners often introduce one compound at a time so effects can be attributed correctly.

With growth-hormone secretagogues such as ipamorelin or CJC-1295, blood pressure and resting heart rate are the main monitoring points, because Cardiogen can shift chronotropic responses in animal models ².

Cardiogen the peptide has no FDA or EMA approval and no published human trial data. It is not scheduled under the US Controlled Substances Act, and it has no USP/NF monograph, so it cannot lawfully be compounded as an approved pharmaceutical ingredient in the United States. In practice it circulates through gray-market research or peptide-supplement channels ¹.

A separate product, CardioGen-82, is an FDA-approved strontium-82/rubidium-82 generator for cardiac PET imaging. FDA alerts, a 2011 recall, and a later Boxed Warning involved strontium breakthrough from that device, not the peptide ⁷. The shared name causes most of the regulatory confusion in the literature.

For sport, Cardiogen is not named on the WADA Prohibited List and does not resemble the listed growth-hormone peptide classes. The realistic competition risk is gray-market contamination or mislabeling, since an undeclared prohibited peptide in a product can still produce an adverse analytical finding.

No human safety trials, pharmacokinetic studies, or case reports exist for Cardiogen, so the profile below is assembled from animal studies, tissue-culture work, the broader peptide class, and practitioner reports.

• Animal and in-vitro data: Injected Cardiogen normalized heart rate, rhythm, and organ mass in stressed rats without a reported adverse signal ². Cultured myocardial tissue showed no reported toxicity ⁵. Broader class-level animal work reported reduced tumor incidence and extended lifespan in treated cohorts ¹, but these are not Cardiogen-specific safety results.
• Practitioner-reported effects: The standard 10-day course is generally described as well tolerated. Reported issues are mild and transient: injection-site reactions, occasional early palpitations, occasional fatigue or headache. No dose-dependent toxicity was reported in the available rat abstract ².
• Caution areas: The sarcoma finding is directionally unclear, so caution is warranted with active or recent cancer ⁴. Combining Cardiogen with beta-blockers, ivabradine, or digoxin could add to heart-rate lowering, inferred from the animal stress model ². Unstudied groups include pregnancy, lactation, children, and people with unstable cardiac disease.

Monitoring suggestions center on resting heart rate and rhythm, plus standard injectable safety labs before repeat courses. These remain preclinical findings, not human safety conclusions.